FindMyKOL

Tamara Vokes

Basic profile

University of Chicago

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionChicago, IL · MidwestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding1985–2007Why? →

Tamara Vokes is an Endocrinology/Metabolic physician affiliated with University of Chicago. OpenAlex indexes 135 publications with 4,619 citations (h-index 31); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
135publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

4,619citations

Citations across these publications.

31h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
7companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 1985–2007

Federally funded research awards.

View funding ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Ascendis Pharma Endocrinology Inc
    Program year202561 payments
    $85,609
  • Takeda Pharmaceuticals U.S.A., Inc.
    Program year20251 payment
    $1,558
  • Takeda Pharmaceuticals U.S.A., Inc.
    Program year20241 payment
    $1,523
All 16 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2022)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    83.7%
    l-Thyroxine59.6%
    Levothyroxine Sodium83%Synthroid17%
    Part D<11 patients
    Parathyroid Hormone-Related Peptide Analog14.9%
    Tymlos100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    16.3%
    Vitamin D3 Analog16.3%
    Calcitriol100%
    Part D<11 patients
Where care is delivered (Part B)77.6% facility · 22.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 1985–2007 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”